RAAV with chemically modified capsid
The invention is directed to the field of gene therapy, i.e. gene delivery into target cells, tissue, organ and organism, and more particularly to gene delivery via viral vectors. The inventors showed that it is possible by chemical coupling to modulate the coupling of a ligand in the surface of the capsid of AAV, for example AAV2 and AAV3b. In particular, the present invention relates to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. Particularly, the inventors tested the chemical coupling of mannose ligand on AAV2 for subretinally injection to rats. The present invention further relates to a method for chemically coupling an Adeno-Associated Virus (AAV) vector particle with at least one ligand L and to a Recombinant Adeno-Associated Virus (rAAV) vector particle obtained by said method as well as a pharmaceutical composition comprising it and their corresponding medical use.
1. A method of delivering a nucleic acid to a cell, the method comprising contacting a cell with an AAV vector particle comprising a ligand covalently linked to a primary amino group of an AAV capsid polypeptide via a -CSNH- bond and a nucleic acid to be expressed in the contacted cell.
2. The method of claim 1 , wherein the contacting is in vivo.
3. The method of claim 2 , wherein the contacting comprises systemic administration.
4. The method of claim 1 , wherein the ligand comprises a mannose, galactose or N-acetylgalactosamine moiety. and the particle targets a cell in the central nervous system.
5. The method of claim 1 wherein the ligand comprises a mono- or polysaccharide moiety.
6. The method of claim 5 , wherein the ligand comprises a mannose, galactose or N-acetylgalactosamine moiety.
7. The method of claim 1 wherein the contacting comprises intrathecal, intracranial, intracerebral, or retinal administration.
8. The method of claim 1 , wherein the ligand comprises a mannose, galactose or N-acetylgalactosamine moiety, and the particle targets a cell in the eye.
9. The method of claim 1 wherein the contacting comprises contacting a cell of an eye or a conjunctival administration.